anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
This invention relates to Schiff&#39;s bases derived from amino acids and hydroxyaryl alkyl ketones, or a plant extract containing the same, having general chemical structure in FIG.  1  for topical application. This invention also relates to certain metal complex of said Schiff&#39;s bases, which have a crown-like appearance in their three-dimensional chemical structure, as in FIG.  2 . The Schiff&#39;s bases and their metal complexes of the present invention are useful for the modulation of metal-activated enzymes and metalloenzymes, such as Phenylalanine Hydroxylase, Tyrosine Transaminase, Phenylalanine Transaminase, Tyrosinase, various MMP (Matrix metalloproteases), Superoxide dismutase, 5-Alpha Reductase, and citrate lyase. These are further suitable for multifunctional topical methods for skin whitening, skin wrinkles reduction, skin antiaging, collagen synthesis, acne control, hair loss prevention, hair graying control, and facial oil control.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for utilizing a gene specific to various types of cancer.  &lt;P&gt;SOLUTION: Hybridization is carried out on slides obtained by preparing RNAs from 38 cell strains derived from lung cancer, 3 normal fibroblast strains, 43 clinical specimens of the lung cancer and 6 normal pulmonary tissues, labeling them with a fluorescent material, and immobilizing 7685 kinds of gene fragments thereon. Usual hierarchical clustering is applied thereto, and the whole cell strains and clinical specimens are separated to each different cluster. The gene expression profile influenced by each type of diseases is considered to be obtained by removing genes commonly highly expressing or lowly expressing in the cultured cell strains or the clinical specimens from the analysis, and a filtering method enabling the removal is newly considered and carried out. As a result, the gene exhibiting disease type-specific expression profile can be identified. The gene is considered to be useful in diagnosis and therapy of each type of the cancer.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Disclosed is a novel amide compound or a salt thereof which has a biofilm formation inhibitory activity or an activity of separating and removing an already-made biofilm. Also disclosed is a biofilm formation inhibitor or biofilm remover containing such an amide compound or a salt thereof as an active ingredient. The amide compound or a salt thereof is represented by the following general formula (1). (In the formula (1), R&lt;sup&gt;1&lt;/sup&gt; represents a hydrogen atom or a hydroxy group; R&lt;sup&gt;2&lt;/sup&gt; represents a C5-12 alkyl group; and Q represents a substituent represented by the following formula (Q1) or (Q2). (In the formulae, n and m independently represent 0 or 1.) The biofilm formation inhibitor and the biofilm remover contain such an amide compound or a salt thereof as an active ingredient.
Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer&#39;s disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed. These uses include the treatment and prevention of amyloid plaques in Alzheimer&#39;s disease and Down&#39;s Syndrome.
Marek&#39;s disease virus (MDV), the etiologic agent of Marek&#39;s disease, is a potent oncogenic herpesvirus. MDV is highly contagious and elicits a rapid onset of malignant T-cell lymphomas in chickens within weeks after infection. MDV codes for an oncoprotein, Meq, that shares resemblance with the Jun/Fos family of b-ZIP transcription factors. Earlier studies showed that Meq is responsible for development for T-cell lymphomas in chicken. In order to identify specific regions within the Meq gene, a series of recombinant MDV were generated in which a mutated gene was introduced in place of parental Meq gene. Various mutations were introduced at the phosphorylation sites, basic region, leucine zipper region and transactivation regions of the Meq gene. Several of these mutations have been shown to have an attenuated phenotype in chickens. In one embodiment, the present invention contemplates exploiting these mutations to develop MDV vaccines that are able to protect against challenge with highly virulent MDV strains.
PURPOSE:To obtain a cosmetic, excellent in stability to oxidation and having expected effects, such as humectant, hair tonic action, etc., for a long period by blending an essential an essential fatty acid or a derivative thereof with an antioxidant, such as dibutylhydroxytoluene, lecithin and phosphoric acid, etc. CONSTITUTION:A cosmetic obtained by blending 0.1-10wt.% 18-22C free fatty acid (e.g. linoleic acid or alpha-linolenic acid) having &gt;=2 unsaturated bonds, salt or ester thereof with 0.001-5.0wt.% antioxidant, lecithin (e.g. soybean lecithin or egg yolk lecithin) and a compound selected from phosphoric acid (salt), an aliphatic hydroxy polybasic acid (e.g. gluconic acid), carboxyvinyl polymer, etc. Dibutylhydroxytoluene, butylhydroxyanisole, erythorbic acid, sage extract, rosemary extract, etc., are used as the antioxidant. The effects are enhanced by use thereof with the lecithin in combination.
An interactive, computerized system that enables physicians and other diagnostic healthcare providers to collaborate on patient&#39;s conditions. Communications are facilitated between and among providers and healthcare professionals, but do not require all parties to be using the system concurrently. Past medical cases, including multiple visits by the same party, in the form of text files, graphics, X-rays, still photographs, moving video images, sound and any combination thereof can be reviewed and used for research and study. Information can be accessed and professionals can collaborate and render multiple opinions. Participants can be educated to retrieve, assemble and share the information. A user (provider, healthcare professional or participant) first logs on to the information system. The user then searches for an entity having at least one identifier or characteristic of interest, and a result set is retrieved. The user then selects one of a group of entities if more than one result is obtained. The user can then communicate the information to professionals and participants for further analysis.
PURPOSE:To provide a new compound having excellent cyclic GMP phosphodiesterase-inhibiting action and useful as an agent for the prevention and treatment of various diseases caused by the enzyme, e.g. a hypotensive diuretic agent or a bronchodilator. CONSTITUTION:The compound of formula (R is n-pentyl, 3-methyl-n-pentyl, n-hexyl, 5-methyl-n-hexyl, n-heptyl or 5-methyl-n-heptyl). The compound can be produced by culturing a bacterial strain belonging to the genus Streptomyces and capable of producing WS63967 substance [Streptomyces griseochromogenes (FERM BP-3659)] in a nutrient medium containing carbon and nitrogen sources under aerobic condition, extracting with a solvent and purifying the extract. The compound of formula has the following properties. Appearance, dark green plate crystal; solubility, easily soluble in DMF and DMSO, slightly soluble in acetone, chloroform and methanol, insoluble in water; color reaction, positive to cerium sulfate reaction and iodine vapor reaction and negative to Molisch&#39;s reaction.
The invention relates to a plaster for treating rheumatalgia and scapulohumeral periarthritis. The plaster is characterized by being mainly prepared from the following raw materials in parts by weight: 20-40 parts of radix aconite, 30-50 parts of root of common peony, 40-60 parts of radix angelicae, 30-80 parts of fructus forsythiae, 50-80 parts of honeysuckle, 30-50 parts of Bletilla striata, 30-50 parts of cinnamon, 40-80 parts of turmeric, 40-60 parts of pseudo-ginseng, 20-40 parts of Chinese honey locust, 40-80 parts of Chinese Starjasmine stems, 30-50 parts of dragon&#39;s blood, 80-100 parts of Alangium platanifolium and 70-90 parts of rhizoma smilacis glabrae. The preparation method of the plaster comprises the following steps: soaking the medicines in sesame oil for 5-7 days; decocting by moderate heat till the decoction is brown; filtering the medicines to obtain medicine oil; decocting the medicine oil by strong fire; stirring the medicine oil by a peach branch, a plum branch, a willow branch, a Chinese scholar tree branch or a mulberry branch; cooking till water drops into beads; and putting the medicine oil on oil paper to obtain the plaster. During use, the plaster is applied to the affected part and changed every 1-2 days in summer and 3-5 days in winter. Seven days are a course of treatment. After two courses of treatment, 70-90% of patients substantially regain the health. The plaster provided by the invention is simple to prepare, convenient to use, quick-acting, good in effect, capable of relieving pains and low in cost, can effectively treat arthralgia such as rheumatalgia, scapulohumeral periarthritis and osteoproliferation, and meanwhile can be used for treating traumatic injuries.
PURPOSE:To obtain an enteric sustained release pharmaceutical preparation for oral use, composed of a composition containing a hydrophilic gelling agent and a medicine and having the surface thereof coated with an enteric film. CONSTITUTION:This enteric sustained release solid pharmaceutical preparation is obtained by coating the surface of a composition containing a hydrophilic gelling agent capable of gelling by including water therein (e.g. hydroxypropyl cellulose) and a medicine such as 5-aminosalicylic acids with an enteric film to 80-120mum thickness in the case of, e.g. a capsule according to a usually used coating technique. The surface is insoluble in gastric juice and readily dissolved in intestinal juice and the contained medicine absorbs water in the enteric canal to gelatinize. Thereby, the dissolution rate is delayed and the medicine further sticks and stays in the interior of the intestines to prolongably and sustainedly release the active ingredient. Absorbing effects can be improved and pharmacodynamic effects can sufficiently be produced by applying this application dosage form as a therapeutic agent for Crohn&#39;s disease or ulcerative colitis.
A system and a method for controlling access of a user&#39;s health information stored over a health care network are described. The method includes providing a Health Information Exchange (HIE) server implemented over a blockchain network. Further, a user device is present in communication with the HIE server. An access of the user&#39;s health information may be provided to a third party user based on a user&#39;s permission. The user&#39;s health information may be stored in at least one of the HIE server and the user device. Further, the user&#39;s health information may be updated using a wearable device worn by the user.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a perfume composition reducing subcutaneous fats, etc., or preventing accumulation because obesity is usually referred to as a state in which surplus energy is converted into fats (triglycerides) with fat cells composing a fat tissue to excessively accumulate the fats in the fat cells and the ratio occupied with the fat tissue in components composing the body is abnormally increased by ingesting energy in a larger quantity than that required by the body with the result that the obesity with great accumulation as the body fats not only is unfavorable in aspects of beauty culture but also involves a risk of causing various diseases such as arteriosclerosis.  &lt;P&gt;SOLUTION: The perfume composition comprises cognac oil (wine lees oil) or mate oil (obtained by solvent extraction of a leaf of Ilex paraguayensis A. St. Hil.) promoting the lipolysis. An external preparation for skin or a food comprises the perfume composition.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE: To obtain a cosmetic capable of giving excellent feeling to the skin such as soft and moist feeling after use by compounding a natural water just collected. CONSTITUTION: This cosmetic is produced by compounding a natural water just collected (preferably, a natural water collected at the foot of Mt. Fuji, Rokkou mountain in Hyogo prefecture, Tanigawadake mountain in Gunma prefecture, etc.). A compounding ratio of the natural water is preferably &gt;=3wt.% based on the total amount of the cosmetic. However, it is preferably &gt;=2wt.% for a solid cosmetic having a stick-shape, a pencil-shape, etc., such as a lipstick. Further, the natural, water is preferably added together with an water-soluble antibacterial agent such as benzoic acid, salicylic acid, etc., after collection. The antibacterial agent is preferably added at a time before bacteria get into a logarithmic growth phase in the natural water, concretely within 3 days after collection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a transdermal transport device with a steam generating actuator.  &lt;P&gt;SOLUTION: A control unit 38 of the device 10 operates the actuator 52. As the actuator 52 is operated to increase the volume inside a chamber 59 by electrolytic effects, a cap 56 is pressed against a rigid upper section 50 of a vial 40 and the vial 40 is pressed downward. As a result, a flexible film 48 is pushed toward an arched section 68 of a base plate 39 while an end 64 of a micro-needle 14 enters a reservoir 46 through the film 48. As a medicament is pushed out into the dermis through a hollow path, a bore, of the micro-needle. In this way, the medicament can be applied at an accurate position just under the corneal layer of epidermis by the device 10.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To conduct a makeup of keratin fiber, in particular eyelashes, eyebrow and the hair, by applying thereto a composition comprising aqueous dispersion (s) of film-forming polymer particles. SOLUTION: This makeup of substantially longitudinal keratin fiber or an equivalent thereof is conducted by applying thereto a composition comprising at least one aqueous dispersion of film-forming polymer particles; wherein the composition which has a viscosity of 0.001-2 Pa.s determined at a shear rate of 500 s&lt;-1&gt; , is applied at such a rate as to allow a film to adhere to the keratin fiber and also pearls to adhere to the keratin fiber surface; the film-forming polymer is pref. a radical polymer (pref. vinyl polymer formed by polymerizing an α,β-ethylenically unsaturated carboxylic acid or the like), a multiple condensate (pref. polyurethane) or a polymer of natural origin (pref. shellac or the like); the above composition preferably contain at least one thickening agent (pref. cellulose thickening agent or the like) as well.
A vaccine comprises antigens derived from myxoviruses inactivated by a process which comprises contacting the viruses in aqueous suspension at pH 6-8 in the presence of at least about 0.05% w/v. of a non-ionic hydrophilic surface active agent with a fully or partially chlorinated, or chlorinated and fluorinated C1-5 hydrocarbon, other than CHCl3, which is liquid at 15-25 DEG C. Specified myxoviruses are M. influenzae-A, B, and C, M. parainfluenzae-1, 2, 3, and 4, M. multiformae, M. pestigalli, M. parotidis, measles virus, distemper virus, rinder-pest virus, and respiratory syncytical virus.  The non-ionic surface active agent may be a polyoxyethylene sorbitan mono-oleate or another polyoxyalkylene ether of partial lauric, palmitic, stearic or oleic acid esters. Specified halogenated hydrocarbons are CCl4, CHCl= CCl2, CCl2=CCl2, CFCl2.CClF2, CCl3.CH2.CCl3 and Cl2.C=C.Cl-C.Cl=C.Cl2.  Any strain of the selected virus may be used.  The virus may be cultivated on chick embryo or monkey kidney tissue cultures, stable diploid cell line culture or, where appropriate, in embryonated hens&#39; eggs.  The tissue culture fluid or harvested allantoic fluid is clarified and the virus therein is inactivated by contact with the above organic solvent. The organic solvent is subsequently removed, leaving an aqueous suspension containing inactivated fragmented virus particles, i.e. the primary vaccine.  Stabilizers, e.g. polyvinyl pyrrolidone or dextran, and protamine sulphate, may be added.  The primary vaccine may be purified or concentrated, e.g. by adsorbing the fragments of inactivated virus on to aluminium oxide or hydroxide or an aluminium salt (e.g. phosphate or alum) substantially isoluble at pH 6-8. Alternatively, a soluble aluminium salt may be added in solution to the primary vaccine and alum precipitated therefrom by the addition of an appropriate potassium salt and adjustment of pH to the required value.  The adsorbate may be separated and resuspended in a saline solution buffered to pH 6.0-8.0.  The purified or concentrated vaccine may be mixed with other vaccines, or the aluminium salt, oxide or hydroxide may be used to adsorb other materials having different antigenicity.
Provided are compositions and methods that include a&lt;i&gt; K. pneumoniae&lt;/i&gt; yidR protein or an antigenic segment of the protein, and homologous of the protein, and antigenic segments of the homologs. The compositions can be provided as vaccine formulations for use with humans and non-human animals, including but not limited to dairy cows. The compositions and methods are useful for prophylaxis and/or therapy of conditions associated with Gram negative bacteria that include &lt;i&gt;K. pneumonia&lt;/i&gt;, &lt;i&gt;E. coli&lt;/i&gt;, and other pathogenic Gram negative bacteria. The conditions include such bacterial infections generally, and include specifically mastitis and metritis. The compositions and methods can also improve fertility and milk production. Administration of the compositions can improve the likelihood of a first service conception.
The invention discloses a Chinese herbal medicament additive for preventing chicken pyreticosis, comprising astragalus, lanceolata, honeysuckle, forsythia, isatis root, goose grass, cicada shell, barrenwort, haw, banksia rose, and cynomorium songaricum. The medicaments above are made into fine powder (200 orders) and mixed homogeneously, and 0.5kg medicament powder is charged into 100kg feedstuff (basal diet) during the utilizing. After the chicken eats the medicament, the invention can advance the digestion and absorption of the chicken, reinforce the appetite, increase the growing speed, and averagely reduce the morbidity of the chicken by 94.75%. The laying rate is increased by 0.2-5%, and the weight of the egg is averagely increased 0.68-2.9g. After using the additive, the input-output ratio is enhanced by 2.5-10%, and the cost of each kilogram of eggs is reduced by 0.3-0.7 yuan. The additive has wide material source, security and nontoxicity, and low price. Moreover, the invention is unable to produce drug resistance, and the chicken product doesn&#39;t have medicament residues, thereby the invention is a perfect additive succedaneum.
FIELD: medicine, immunology. SUBSTANCE: extraction of an alcoholic precipitate B (Cohn&#39;s fraction III) is carried out in 10-fold volume of distilled water and sodium chloride (final concentration is 0.9%, by volume) is used for lipoprotein fraction removing. Immunoglobulin fraction is precipitated from extract in the presence of 12% polyethylene glycol. Content of inert impurities in preparation is 0-1% of total protein as compared with that 3-5% in prototype. Specific activity is increased by 2-3 times and the yield of preparation - by 1.5-fold. Net cost of the end product is decreased by 25% as compared with that in prototype. EFFECT: enhanced purity, increased specific activity and yield of preparation.
Medicaments contain (a) one or more of the plasma proteins whose concn. is increased by the pathological process, or (b) a plasma protein mixt. contg. a plasma protein as defined in (a), or (c) an endogenous mediator, esp. a leucocytic endogenous mediator (LEM), which induces the change in plasma protein concn. specific to the pathological process. The medicaments stimulate the body&#39;s defence mechanism against the pathological process. Prefd. active ingredient is fibrinogen.
The present invention relates to a liquid crystal display device, which includes a display module and a first frame, which includes a plurality of side walls. A flexible configuration is disposed onto the inner surface of at least one of the side walls. The flexible configuration includes a flexible arm, a contact part which is connected to the flexible arm, and a resistive part which is disposed at one end of the contact part. The resistive part keeps a distance to the inner surface of the side wall. When the pressure to the flexible arm is unbearable, the resistive part sticks up to the side wall in order to prevent the flexible arm from breaking off. The back case can cooperate with different standard display panel and needn&#39;t to redesign the plastic mould.
PROBLEM TO BE SOLVED: To obtain a preparation for external use such as for a cosmetic material, capable of effectively suppressing various disorders caused by singlet oxygen in living bodies, e.g. immediate melanism generated by the oxidation of DOPA by allowing to contain a compound having a specific reaction rate constant with a singlet oxygen as an effective component. SOLUTION: This preparation for external use contains a compound having &gt;=1×10&lt;6&gt; M&lt;-1&gt; s&lt;-1&gt; reaction rate constant with a singlet oxygen as an effective component and preferably a UV absorber (e.g. 4-t-butyl-4&#39;- methoxydibenzoylmethane, etc.). To screen the compound, e.g. is to irradiate laser of a UV ray wave length to a system in which generation of the singlet oxygen is known, measure a minute emission in the near infrared region which is specific to the singlet oxygen, then measure the emission when a compound to be tested is added to the same system and calculate the constant from the reduction of the emission in the near infrared region and, as a concrete example, β-carotene can be used for this purpose.
DRD1 is a kind of dopamine receptors, is widely distributed in nervous systems and can activate protein kinase A, a downstream signal path and a cytomembrane ion path by positively regulating and controlling cAMP to take various important physiological actions. Proved by plenty of documents, the expression quantity and the activity of DRD1 are directly and importantly related to Parkinson disease, drug abuse, abnormal relevant diseases on learning and memory and the like. Recent years, a plurality of documents prompt that a cis-acting element in mRNA 3&#39;UTR takes critical action on regulating and controlling gene expression. The invention mainly identifies the cis-acting elecment, i.e. ARE element having remarkable regulation and control action on the gene expression of DRD1 is identified on mRNA 3&#39;UTR, determines the interaction molecules, i.e. HuD protein and confirms the discovery in P19 cell line. The invention provides a critical target spot for researching and developing a new medicine for treating relevant nervous system diseases because of the abnormal expression of DRD1 and provides an important technological path for developing relevant molecular biology treatment protocols.